Latest news with #Medtronic
Yahoo
7 hours ago
- Health
- Yahoo
Medtronic's MiniMed 780G system gains CE Mark for expanded indications
Medtronic's MiniMed 780G system has received European CE Mark approval to expand the indications for use by people aged two years and above, during pregnancy, and for those with type 2 insulin-requiring diabetes. The approval follows a review of published clinical data encompassing two to six-year-olds, pregnant women, and those with type 2 diabetes (T2D). The LENNY trial highlighted the efficacy and safety of the MiniMed 780G system in children aged two to six years with type 1 diabetes (T1D). Subjects who used the system in auto mode achieved a 0.6% reduction in HbA1C and a 9.9% increase in time in range against manual mode. An improved sleep quality and reduced fear of hypoglycaemia in the auto mode were reported by parents and caregivers. The company noted that the pregnancy poses distinct challenges for glucose management in women with T1D. The MiniMed 780G system's ability to address lower glucose levels offers a potent tool for maintaining tighter control, the company added. Additionally, a European study showed that women using the system during pregnancy achieved an average Pregnancy Time in Range (TIRp) of 66.5%, against traditional insulin therapy. The system has also proved beneficial for individuals with T2D. A pivotal trial reported a 0.7% decrease in HbA1c and an 80% increase in TIR. Real-world data from 26,427 T2D users of the system indicated good glycaemic control, with TIR exceeding international consensus targets. The company is working with the US Food and Drug Administration (FDA) to expand the system's use to a broader population, including individuals with T2D and young children. The SmartGuard algorithm within the system is said to automate insulin delivery based on continuous glucose monitoring (CGM) readings. The system is tailored to be used at an adjustable target glucose of 100mg/dl (5.5mmol/L) and customised on an individual basis. This month, Medtronic obtained CE mark approval for LigaSure RAS, a vessel-sealing instrument for use with the company's Hugo robotic-assisted surgery (RAS) system. "Medtronic's MiniMed 780G system gains CE Mark for expanded indications" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Business
- Yahoo
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Medtronic (MDT) was up +2.17% at $91.65. This move outpaced the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.41%, and the Nasdaq, a tech-heavy index, lost 0.39%. The stock of medical device company has risen by 4.35% in the past month, leading the Medical sector's loss of 1.83% and undershooting the S&P 500's gain of 5.88%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on August 19, 2025. In that report, analysts expect Medtronic to post earnings of $1.23 per share. This would mark no growth from the year-ago period. Alongside, our most recent consensus estimate is anticipating revenue of $8.37 billion, indicating a 5.73% upward movement from the same quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.55 per share and a revenue of $35.29 billion, indicating changes of +1.09% and +5.22%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. Medtronic is currently a Zacks Rank #4 (Sell). From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 16.17. Its industry sports an average Forward P/E of 18.47, so one might conclude that Medtronic is trading at a discount comparatively. It is also worth noting that MDT currently has a PEG ratio of 2.33. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.22. The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 177, which puts it in the bottom 29% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Reuters
2 days ago
- Business
- Reuters
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict
July 18 (Reuters) - A U.S. appeals court on Friday overturned a jury's verdict that medical device maker Medtronic (MDT.N), opens new tab owes competitor Colibri $106.5 million for infringing a patent related to heart valve technology. The U.S. Court of Appeals for the Federal Circuit determined, opens new tab that a California judge should have ruled before the trial that Minneapolis-based Medtronic's devices did not violate Colibri's patent rights. Medtronic said in a statement that the decision "affirms our longstanding position that Colibri's patent infringement claims lacked merit." Spokespeople and an attorney for Colibri did not immediately respond to requests for comment. Colorado-based Colibri alleged in a 2020 lawsuit that Medtronic's Evolut devices for replacing heart valves in heart disease patients infringed a Colibri patent related to deploying artificial heart valves. The patent relates to Colibri's competing heart valve implant system. Colibri said in the lawsuit that company officials shared information about its patented technology with Medtronic in 2014, before Medtronic introduced its Evolut system. A jury found in 2023 that Medtronic's devices infringed Colibri's patent. A three-judge Federal Circuit panel overturned the verdict on Friday, agreeing with Medtronic that the district court judge should have ruled for the company before the case went to a jury trial. The case is Colibri Heart Valve LLC v. Medtronic CoreValve LLC, U.S. Court of Appeals for the Federal Circuit, No. 23-2153. For Colibri: Jeffrey Lamken of MoloLamken For Medtronic: Greg Castanias of Jones Day Read more: Medtronic hit with $106.5 mln U.S. verdict in heart-valve patent case
Yahoo
2 days ago
- Business
- Yahoo
Medtronic's $106m heart valve patent infringement ruling overturned
The US Court of Appeals has overturned a $106.5m ruling wherein a California court jury found that Medtronic infringed on a heart valve replacement method developed by Colibri Heart Valve. Colibri sued Medtronic in 2020, alleging that the medtech giant's Evolut transcatheter aortic valve replacement (TAVR) systems for treating severe aortic stenosis infringed on its patented method for controlled release of replacement heart valves. The Colorado-based company's filing with a California court alleged that Medtronic's systems infringed on its patented method (No. 8,900,294) of partially deploying a replacement valve from the delivery apparatus and recapturing the valve within the delivery apparatus before full deployment if it looks like the positioning will be off. Colibri's lawsuit asserted that Medtronic learned about its patented methods in a 2014 conference call and during a presentation given by Colibri CEO Joseph Horn about its technology to Medtronic's marketing director and senior clinical programme manager. The patent claimed the 'do-over' method of partial deployment could involve pushing out the valve from an outer sheath of the delivery apparatus or retracting the outer sheath to expose the valve. The case went to trial in 2023, with Medtronic attesting that the accused's use of its product involved partial deployment by retracting, not pushing. During the trial, Colibri dropped its initial assertion of 'literal' infringement and relied solely on the doctrine of equivalents to establish patent infringement using the accused method. Medtronic sought judgment as a matter of law (JMOL) to get this change rejected, deeming the entire premise of the lawsuit invalid; however, the invalidity challenge was rejected. Medtronic was subsequently found to have 'induced infringement', with Colibri awarded $106.5m in damages. The overrule from the US Court of Appeals read: 'We now conclude that prosecution history estoppel, based on Colibri's cancelling of a claim to 'retraction' for partial deployment of the replacement valve and Colibri's own recognition of the close linkage of the subject matter of the cancelled and retained claims, bars application of the doctrine of equivalents. We therefore reverse the district court's denial of JMOL of noninfringement.' A Medtronic spokesperson told Reuters that the court outcome 'affirms our longstanding position that Colibri's patent infringement claims lacked merit". Medical Device Network has reached out to Colibri for comment. "Medtronic's $106m heart valve patent infringement ruling overturned" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever
Key Points Dividend stocks are a useful source of extra income. The best dividend stocks, however, also increase payouts over time and can build you a fortune. The S&P 500 index has some top-notch dividend stocks, some of which are no-brainer buys now. 10 stocks we like better than Medtronic › Dividend stocks are one of the most powerful wealth compounders. The S&P 500 (SNPINDEX: ^GSPC) index offers the perfect example. Over the past 25 years, while the S&P 500 rose by over 300%, its total returns crossed 550% thanks to reinvested dividends. As you may guess, the S&P 500 comprises some of the best dividend stocks out there, many of which have been multibaggers and have the potential to continue being so. Here are 10 such magnificent S&P 500 dividend stocks -- trading at least 10% below their all-time highs -- to buy now and hold forever. Johnson & Johnson: down 11.5%, yield 3.4% Johnson & Johnson (NYSE: JNJ) is a cash-flow machine. It generated $95 billion in free cash flow (FCF) over the past five years and returned 60% of it to shareholders. The stock is also a dividend powerhouse, increasing its dividend for 62 consecutive years. Johnson & Johnson has robust financials, invests heavily in research and development, and has big plans for both its businesses, pharmaceuticals and medical technology, making it a top S&P 500 dividend stock to buy and hold. ExxonMobil: down 11.6%, yield 3.7% ExxonMobil (NYSE: XOM) is one of the world's largest oil and gas companies. In 2024, the oil and gas giant generated $55 billion in cash flow from operations, compared to $30 billion in 2019. ExxonMobil is a dividend behemoth with a 42-year streak of consecutive dividend increases. After its $60 billion acquisition of Pioneer Natural Resources in 2023, ExxonMobil has been targeting higher production at even lower costs and focusing on boosting its cash flows, all of which makes this magnificent S&P 500 dividend stock a buy at every dip. Procter & Gamble: down 14%, yield 2.7% Procter & Gamble (NYSE: PG) owns over 60 brands, most of which are household names today. Although its organic sales growth has slowed due to higher costs and weak consumer sentiment, it's just a short-term blip. Procter & Gamble is restructuring operations and targeting core earnings per share by mid- to high-single-digit percentages in the long term by exiting low-margin brands and markets. Above all, Procter & Gamble has a strong balance sheet and is a Dividend King, having increased its dividend for 69 consecutive years. NextEra Energy: down 19%, yield 3.3% NextEra Energy (NYSE: NEE) operates the largest electric utility in America (Florida Power & Light), which generates steady cash flows. It is also the world's largest producer of wind and solar energy, as well as a key player in battery storage, all of which are growth drivers. NextEra Energy stock has increased its dividend for over 20 years and has generated humongous returns for investors who reinvested the dividends. The global shift to renewables and a massive pipeline make NextEra Energy a no-brainer S&P 500 dividend stock to buy and hold forever. Chevron: down 19%, yield 4.8% Chevron (NYSE: CVX) is one of the largest integrated oil companies, operating across the entire value chain, from exploration and production to pipelines, refining, chemicals, and marketing. Chevron has massive oil and gas reserves but is also growing new low-carbon businesses, such as hydrogen and renewable fuels. Chevron has increased its dividend for 38 consecutive years, making it one of the best oil dividend stocks within the S&P 500. Chevron also just won a dispute with ExxonMobil and has acquired Hess in a massive $53 billion deal. American Water Works: down 24%, yield 2.4% American Water Works (NYSE: AWK) is the largest regulated water and wastewater utility in the U.S., serving over 14 million customers and 18 military bases. While generating stable cash flows from these regulated and contracted businesses, American Water Works' regular investments in its infrastructure help it secure base rate hike approvals, which continue to drive its earnings, cash flows, and dividends higher. American Water Works is targeting 7% to 9% annual dividend growth for the long term, making it an incredibly safe S&P 500 dividend stock to buy now and hold forever. Realty Income: down 29%, yield 5.6% Realty Income (NYSE: O), a real estate investment trust (REIT), pays a dividend every month and has increased it for 110 consecutive quarters now. The company owns over 15,000 properties globally and leases them under triple-net leases, where the tenants bear most of the costs. So, Realty Income enjoys high margins, and its diverse portfolio enables the company to navigate economic challenges. Realty Income's commitment to paying a monthly and growing dividend makes it one of the top 10 dividend stocks to double up on now and hold. Oneok: down 29%, yield 5% Oneok (NYSE: OKE) is one of the largest energy infrastructure companies in the U.S., with a network of pipelines spanning 60,000 miles. Three big acquisitions over the past couple of years or so, including that of Magellan Midstream Partners, combined with organic expansions, should help Oneok steadily grow earnings and meet its goal of increasing the annual dividend by 3% to 4%. When coupled with a 5% yield, Oneok makes for an appealing S&P 500 dividend stock to buy and hold. Nucor: down 30%, yield 1.7% Nucor (NYSE: NUE) is America's largest and most diversified steel company. It is also vertically integrated, meaning it sources the bulk of its raw material in-house. That's a huge competitive advantage to have in a commodity business and one of the key factors behind Nucor's strong financials and dividend growth. Nucor aims to return at least 40% of its earnings to shareholders, has increased its dividend for 52 straight years, and is primed to benefit from President Donald Trump's steep tariffs on steel imports. Medtronic: down 33%, yield 3.3% With revenue of $33.5 billion for the fiscal year that ended April 25, 2025, Medtronic (NYSE: MDT) is the world's largest medical device manufacturer. It offers a wide range of products across cardiovascular, neuroscience, medical-surgical, and diabetes care and uses artificial intelligence and robotics technologies to build better products. Medtronic plans to divest its diabetes business into a separate company to unlock more value for shareholders. Meanwhile, it is only two dividend raises away from becoming a Dividend King, making this S&P 500 dividend stock a solid buy. Do the experts think Medtronic is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Medtronic make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,048% vs. just 180% for the S&P — that is beating the market by 867.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron, NextEra Energy, and Realty Income. The Motley Fool recommends Johnson & Johnson, Medtronic, and Oneok and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
